Mantle cell lymphoma (MCL) can run the gamut from an indolent to aggressive disease, and identifying biomarkers is key in determining which patients should follow a watch-and-wait strategy and ...

Patients who present with indolent mantle cell lymphoma (MCL) have a better prognosis and can often defer treatment for months or sometimes years, but evidence on the best approach for this ...

Fig 1. Progression-free survival (PFS) by treatment group for (A) all patients, (B) patients with indolent non-Hodgkin lymphoma, and (C) patients with mantle-cell lymphoma. Note: Censored values are ...

Patients with an unusually indolent form of mantle-cell lymphoma typically present with splenomegaly, bone marrow involvement, and circulating lymphoma cells but without lymphadenopathy and ...

A patient with relapsed/refractory non-Hodgkin lymphoma received the first dose of a two-step radiotherapy using the ...

Fast-growing lymphomas are called high-grade. Slow-growing lymphomas are called low-grade or indolent. Mantle cell lymphoma is unusual because it can look and act like both high-grade and low ...

The proteasome inhibitor bortezomib is registered in the US for use in multiple myeloma, but its antitumor activity has not been tested in patients with indolent or MANTLE-CELL LYMPHOMA (MCL).

In mantle cell lymphoma, it's a good regimen ... Versus CHOP Plus Rituximab as First-Line Treatment for Patients With Indolent and Mantle-Cell Lymphomas: An Open-Label, Multicentre, Randomised ...

Barta: Outcomes for patients with mantle cell lymphoma are very heterogeneous. Some patients have an indolent course, whereas other patients have a very aggressive course. Furthermore, upfront ...

Mantle cell lymphoma can be challenging to treat because it can manifest as either an indolent disease — known as “classical” mantle cell lymphoma — or it can develop an aggressive course ...

Mantle cell lymphoma grows slowly but can be hard to ... Some types are aggressive (fast-spreading) and some types are indolent (slow-spreading). How aggressive is large B-cell lymphoma?

The medians were not reached for any of the time-to event end points for either the BR or R-CHOP/R-CVP study treatment groups by study completion. PFS rates at 5 years were 65.5% in the BR treatment ...